Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease
- PMID: 2146369
- DOI: 10.1007/BF00314742
Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease
Abstract
The caudate nucleus has the highest acetylcholinesterase (AChE) activity in the brain and it has been shown that autopsied brain tissue of patients with Huntington's disease (HD) have reduced levels of acetylcholine. Because of these findings, the cholinergic function in HD was studied by measuring cerebrospinal fluid (CSF) choline levels and AChE activity during a randomized, double-blind, cross-over, placebo-controlled clinical trial of isoniazid. While mean choline levels adjusted for age were lower compared with controls (P = 0.0007), AChE activity did not differ between HD patients and normal controls. Treatment with isoniazid had no significant effect on CSF choline levels or CSF AChE activity. CSF AChE activity showed a statistically significant increase with advancing age. The reduced level of choline in CSF of HD patients may reflect either a defect in choline transport into the brain or a decrease of choline-phospholipid output from the brain.
Similar articles
-
Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders.Psychopharmacology (Berl). 1979 May 25;63(2):155-9. doi: 10.1007/BF00429695. Psychopharmacology (Berl). 1979. PMID: 157494
-
Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease.Brain Res. 1987 Apr 7;408(1-2):125-30. doi: 10.1016/0006-8993(87)90364-7. Brain Res. 1987. PMID: 2885064 Clinical Trial.
-
Cerebrospinal fluid as a reflector of central cholinergic and amino acid neurotransmitter activity in cerebellar ataxia.Arch Neurol. 1990 Nov;47(11):1194-9. doi: 10.1001/archneur.1990.00530110048016. Arch Neurol. 1990. PMID: 1978660 Clinical Trial.
-
Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease.Life Sci. 1980 Apr 21;26(16):1303-8. doi: 10.1016/0024-3205(80)90089-2. Life Sci. 1980. PMID: 6446011 Clinical Trial. No abstract available.
-
Cerebrospinal Fluid Biomarkers for Huntington's Disease.J Huntingtons Dis. 2016;5(1):1-13. doi: 10.3233/JHD-160196. J Huntingtons Dis. 2016. PMID: 27031730 Review.
Cited by
-
Acetylcholinesterase assay for cerebrospinal fluid using bupivacaine to inhibit butyrylcholinesterase.BMC Biochem. 2001;2:17. doi: 10.1186/1471-2091-2-17. Epub 2001 Dec 21. BMC Biochem. 2001. PMID: 11801199 Free PMC article.
-
Antioxidants Reverse the Changes in the Cholinergic System Caused by L-Tyrosine Administration in Rats.Neurotox Res. 2018 Nov;34(4):769-780. doi: 10.1007/s12640-018-9866-6. Epub 2018 Feb 7. Neurotox Res. 2018. PMID: 29417439
-
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.Curr Neuropharmacol. 2019;17(2):165-175. doi: 10.2174/1570159X16666180302115032. Curr Neuropharmacol. 2019. PMID: 29512464 Free PMC article. Review.
-
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.J Huntingtons Dis. 2016 Dec 15;5(4):333-342. doi: 10.3233/JHD-160200. J Huntingtons Dis. 2016. PMID: 27983560 Free PMC article. Review.
-
A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.J Huntingtons Dis. 2018;7(2):109-135. doi: 10.3233/JHD-170273. J Huntingtons Dis. 2018. PMID: 29614689 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical